Buscar
Mostrando ítems 1-10 de 85
Trabecular and cortical bone involvement in rheumatoid arthritis by DXA and DXA-based 3D modelling
(Springer London Ltd, 2020-09)
Summary: Rheumatoid arthritis (RA) patients had a higher risk of developing low bone mineral density (BMD) or osteoporosis. RA patients on classic disease-modifying antirheumatic drug (c-DMARD) therapy showed significantly ...
Costs and disease activity in patients with rheumatoid arthritis treated with biologic dmards: findings in a real-life setting
(Universidad de la Costa, 2019)
Efetividade clínica dos medicamentos biológicos anti-TNF, biológicos não anti-TNF e sintético alvo-específico no tratamento da artrite reumatoide.
(Universidade Federal de Minas GeraisBrasilFARMACIA - FACULDADE DE FARMACIAPrograma de Pós-Graduação em Medicamentos e Assistencia FarmaceuticaUFMG, 2022-02-24)
Introduction: Rheumatoid Arthritis is a systemic, chronical inflammatory disease
associated to peripheral polyarthritis, which leads to deformity and destruction of
joints due to erosion of cartilage and bone. Treatment ...
Prevalencia en el hospital Teodoro Maldonado Carbo de artritis reumatoide y usos de tratamientos biológicos y no biológicos en el año 2016.
(Universidad Católica de Santiago de Guayaquil, 2017)
Economic Benefit of Sponsored Controlled Clinical Trials: The Avoidable Cost in Drugs for the Treatment of Rheumatoid ArthritisBeneficio económico de los ensayos clínicos controlados patrocinados: El gasto evitable en medicamentos para el tratamiento de la artritis reumatoidea
(Elsevier Inc, 2019-12)
Objectives: To estimate the following: (1) the avoidable cost of biologic (bDMARDs) and conventional synthetic Rheumatoid Arthritis (RA) modifying antirheumatic drugs (csDMARDs) during controlled clinical trials (CCTs), ...
Caracterización epidemiológica de la artritis idiopática juvenil y refractariedad a dmard en una institución en Bogotá
(Universidad del RosarioEspecialización en PediatríaFacultad de medicina, 2016)
Introduction: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood with significant impact on the quality of life of both patients and their families. Its physical alterations could ...
Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry
(BMJ Publishing Group, 2015)
Background There is increasing interest in discontinuing biological therapies for patients with rheumatoid arthritis (RA) achieving good clinical responses, provided patients maintain clinical benefit.
Methods We ...
Antinuclear Antibody (ANA) Testing in Patients Treated With Biological DMARDs: Is It Useful?
(2015)
The appearance of biologic agents for the treatment of diverse autoimmune diseases in particular rheumatoid arthritis at the end of the 1990s changed the treatment of these patients. With the introduction of new agents in ...